News >

Carfilzomib OS Benefit in Myeloma Highlighted in Published Findings

Jason Harris
Published: Thursday, Jan 25, 2018

Keith Stewart, MB, ChB

Keith Stewart, MB, ChB
The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) extended overall survival (OS) for patients with relapsed or refractory multiple myeloma by nearly 8 months compared with lenalidomide and dexamethasone alone (Rd) in results from the phase III ASPIRE trial published in the Journal of Clinical Oncology.

The findings, which were reported at the 2017 ASH Annual Meeting, showed that the median OS was 48.3 months for patients assigned to KRd compared with 40.4 months for those assigned to Rd (HR, 0.79; 95% CI, 0.67-0.95; P = .0045). KRd was associated with an 11.4-month survival advantage in patients at first relapse (47.3 vs 35.9 months; HR, 0.81, 95% CI, 0.62-1.06).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x